Comparative effectiveness of potassium-competitive acid blockers and proton pump inhibitors in dual antiplatelet therapy patients: a nationwide cohort study
International Journal of Clinical Pharmacy · 2025-10 · 47 (5) · 1204-1214
DOI: 10.1007/s11096-025-01895-2 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Clinical Pharmacy, online erschienen am 21.03.2025. Verfasst von Yu Jeong Lee und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Pusan National University, Busandaehakro 63 Bungil 2, Geumjeong-Gu, Busan, 46241, Republic of Korea. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Platelet Aggregation Inhibitors, Coronary Artery Disease, Dual Anti-Platelet Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Proton pump inhibitors (PPIs) are widely used in combination with dual antiplatelet therapy (DAPT) to reduce the risk of gastrointestinal bleeding; however, some PPIs may interfere with clopidogrel metabolism through CYP2C19 inhibition. Potassium-competitive acid blockers (P-CABs) have emerged as alternatives to PPIs, although their effectiveness in patients receiving DAPT have not been sufficiently explored. AIM: This study aimed to compare the effectiveness of PPIs and P-CABs in preventing cardiovascular events and gastrointestinal bleeding among patients receiving DAPT after coronary stent implantation. METHOD: A retrospective cohort design was employed using nationwide claim data from South Korea. The study included patients who received aspirin-clopidogrel DAPT with PPI or P-CAB for a minimum of 60 days. After applying propensity score matching (PSM) at a 1:1 ratio, survival analysis was conducted. The primary outcome was a composite of acute myocardial infarction, ischemic stroke, revascularization, and in-hospital mortality. Secondary outcomes involved the individual components of the composite outcome and gastrointestinal bleeding. RESULTS: The initial cohort included 39,234 patients in the PPI group and 3,434 in the P-CAB group. After 1:1 PSM, 3,434 patients were included in each group. No statistically significant differences were observed between the PPI and P-CAB groups for the primary outcome (hazard ratio [HR], 0.85; 95% confidence interval [CI], 0.68-1.07; p = 0.167) and gastrointestinal bleeding (HR, 1.36; 95% CI, 0.76-2.42; p = 0.3). CONCLUSION: Both PPIs and P-CABs appear to be viable options for acid suppression in patients undergoing DAPT, with no significant differences in cardiovascular or gastrointestinal outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Pusan National University, Busandaehakro 63 Bungil 2, Geumjeong-Gu, Busan, 46241, Republic of Korea.
- Department of Pharmacy, Pusan National University Hospital, Busan, Republic of Korea.
- College of Pharmacy, Pusan National University, Busandaehakro 63 Bungil 2, Geumjeong-Gu, Busan, 46241, Republic of Korea. jenk@pusan.ac.kr.
- Research Institute for Drug Development, Pusan National University, Busan, Republic of Korea. jenk@pusan.ac.kr.
Zitieren
APA
Lee, Y. J., & Je, N. K. (2025). Comparative effectiveness of potassium-competitive acid blockers and proton pump inhibitors in dual antiplatelet therapy patients: a nationwide cohort study. International Journal of Clinical Pharmacy, 47(5), 1204-1214. https://doi.org/10.1007/s11096-025-01895-2
Vancouver
Lee YJ, Je NK. Comparative effectiveness of potassium-competitive acid blockers and proton pump inhibitors in dual antiplatelet therapy patients: a nationwide cohort study. International Journal of Clinical Pharmacy. 2025;47(5):1204-1214. doi:10.1007/s11096-025-01895-2
BibTeX
@article{Lee2025,
author = {Lee, Yu Jeong and Je, Nam Kyung},
title = {Comparative effectiveness of potassium-competitive acid blockers and proton pump inhibitors in dual antiplatelet therapy patients: a nationwide cohort study},
journal = {International Journal of Clinical Pharmacy},
year = {2025},
volume = {47},
number = {5},
pages = {1204--1214},
doi = {10.1007/s11096-025-01895-2}
}
EUVIMED